Article DOI: https://doi.org/10.3201/eid3008.240145

EID cannot ensure accessibility for supplementary materials supplied by authors. Readers who have difficulty accessing supplementary content should contact the authors for assistance.

Infective SARS-CoV-2 in Skull Sawdust at Autopsy, Finland

Appendix

Autopsy facilities and practices

The autopsy facilities at our department include three autopsy suites. All three have negative air pressure, a minimum of 15 air changes per hour, with one suite dedicated to infectious diseases. The dedicated room uses a HEPA-filter for the exhaust air, and all autopsy suites offer a local HEPA-filtered air purifying unit for aerosol control. Two of the COVID-19 cases were done in routine autopsy suites due to unknown infection status, but these cases did not show skull positivity. All the identified COVID-19 cases were autopsied in the dedicated autopsy suite for infectious cases.

The autopsy protocol used en bloc removal of the viscera, and all autopsies included assessment of the central nervous system via craniotomy. The skull was opened using an oscillating saw, under the hood of the local air purifying unit for aerosol control. Cold water was used sparingly, with minimal pressure to avoid aerosol formation.

The personnel involved in the COVID-19 autopsies included five autopsy technicians and four pathologists. One to two pathologists and autopsy technicians were present in the autopsy suite for a single case. The duration of autopsies varied from 1–4 hours per case.

Personal protective equipment (PPE) used routinely consisted of an FFP3 mask, cap, goggles, water resistant gown, double pairs of gloves and boots. A powered air purifying respirator (VersaFlo, 3M) was used in some cases instead of the FFP3 mask and goggles.

SARS-CoV2 tissue processing, virus isolation and quantitative RT-PCR

For SARS-CoV2+ cases fresh tissue samples, swabs (including swabs of skull sawdust and swabs of the contaminated autopsy table with the organ block), cerebrospinal fluid (CSF) and blood were collected at autopsy and transferred to the biosafety level 3 laboratory (BSL-3) for further processing. For virus isolation, tissue samples were homogenized using mortar and pestle and sterile sand with ice-cold PBS. Cleared tissue samples were collected, inoculated on Vero E6 cells, and incubated for 1 h at $+37^{\circ}$ C 5% CO2, after which the cells were washed with PBS and virus growth media containing 2% FCS was added. Virus growth was followed by cytopathic effect (CPE) formation and confirmed by quantitative RT-PCR on day 0 and between days 4–11, with >2-log value increase considered positive. See Appendix Table for culture positive samples per sample category.

RNA was extracted from the tissue samples using TRIzol reagent (Invitrogen) according to the manufacturer's instructions, and from cell culture supernatants using the QIAamp Viral RNA Mini Kit (Qiagen). Quantitative SARS-CoV-2 RT-PCR was performed according to previously published protocol (*1*). See Appendix Table for the tissue with highest SARS-CoV-2 copy number per category.

High SARS-CoV-2 copy numbers correlated with positive viral culture (rank biserial correlation for airway samples $r_{rb} = 0.783$ (n=22) and all cultured samples $r_{rb} = 0.646$ (n=47), both p <0.01), as reported in other studies (2,3). The data in this cohort does not allow for reliable evaluation of the effect of postmortem delay on culture positivity. However, our experience is similar to the findings seen by others, with surprisingly long postmortem delays showing positivity (4).

Serological testing

The autopsy personnel were tested for presence of antibodies after the first wave of infections in June 2020. The tested cohort included all 6 individuals that had known exposure to COVID-19 autopsies at the time of testing. None of the individuals either had symptomatic disease warranting PCR-testing, or their PCR-tests were negative in the time prior to antibody testing. A total of five COVID-19 autopsies were performed during the spring of 2020, with these cases not being part of the cohort reported on here.

Experience on occupational hazards

In our experience FFP3 masks as part of aerosol controlling autopsy precautions seem to protect from airborne infections during autopsy. No cases of autopsy-related COVID-19 were identified among the personnel in Helsinki during the years 2020 - 2023. In addition, no cases of TB have been identified while using the same safety procedures during the years 2011 - 2023. The addition of local exhausts as a source-control with HEPA-filters helps further reduce the amount of potentially infective aerosols in the autopsy room, easing the workload of masks as the single method for aerosol filtering.

References

- Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25:2000045. <u>PubMed</u> <u>https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045</u>
- Huang CG, Lee KM, Hsiao MJ, Yang SL, Huang PN, Gong YN, et al. Culture-based virus isolation to evaluate potential infectivity of clinical specimens tested for COVID-19. J Clin Microbiol. 2020;58:e01068–20. PubMed https://doi.org/10.1128/JCM.01068-20
- 3. Berg MG, Zhen W, Lucic D, Degli-Angeli EJ, Anderson M, Forberg K, et al. Development of the RealTime SARS-CoV-2 quantitative Laboratory Developed Test and correlation with viral culture as a measure of infectivity. J Clin Virol. 2021;143:104945. <u>PubMed</u> https://doi.org/10.1016/j.jcv.2021.104945
- 4. Plenzig S, Bojkova D, Held H, Berger A, Holz F, Cinatl J, et al. Infectivity of deceased COVID-19 patients. Int J Legal Med. 2021;135:2055–60. <u>PubMed https://doi.org/10.1007/s00414-021-02546-7</u>

Appendix	Table. Highest SA	RS-CoV-2 copy	number val	ues per sample	category, wit	th culture positive t	issue type where
applicable,	ranked according	to PCR copy nu	mber*				

				Non-	CNS				
			Non-airway	airway	PCR &	Skull	Skull		Table
Case no.	Airway PCR	Airway culture	PCR	culture	culture	PCR	culture	Table PCR	culture
1	493000 (lung)	-	-	-	-	-	-	1090	-
								(table)	
2	27570 (tonsil)	-	-	-	-	-	-	-	-
3	1114000 (lung)	-	-	-	-	-	-	-	-
4	41170 (tonsil)	-	-	-	-	-	-	-	-
5	176100 (tonsil)	-	-	-	-	-	-	-	-
6	111400 (bronchi)	bronchi, lung,	-	-	-	-	-	6840	-
		tonsil						(table)	
7	18180000 (lung)	lung, tonsil,	15260	-	-	-	-	206 (table)	-
		nasopharynx	(heart)						
8	15000000	cervical lymph	1028	-	-	-	-	-	-
	(cervical lymph	node	(pancreas)						
	node)								
9	5476000	nasopharynx,	8465	-	-	74830	skull	36.87	-
	(nasopharynx)	bronchi, tonsil	(salivary			(skull)		(table)	
			gland)						
10	3552000	bronchi	-	-	-	-	-	8625	-
	(nasopharynx)							(table)	
11	7929000	bronchi	182700	gut	-	-	-	1201	-
	(bronchi)		(gut)					(table)	
12	1504000	nasopharynx	-	-	-	53360	-	-	-
	(nasopharynx)					(skull)			
13	3006	-	-	-	-	-	-	-	-
	(parabronchial								
	lymph node)								
14	365400 (bronchi)	nasopharynx,	13980	muscle	-	-	-	10360	-
		sclera,	(heart)					(table)	
		parabronchial							
		lymph node							
15	134500000	lung	1249	-	-	-	-	9470	table
	(lung)		(salivary					(table)	
			gland)						
16	44870000 (lung)	lung, bronchi	14810	-	-	-	-	3492	table
			(spleen)					(table)	
17	455200 (lung)	-	-	-	-	-	-	32387	-
								(table)	
18	2486000	lung	135.3	-	-	-	-	13550	-
	(nasopharynx)		(salivary					(table)	
			gland)						
19	591700	-	828.5	-	-	-	-	33320	-
	(nasopharynx)		(thyroid)					(table)	
20	6553000 (lung)	lung, tonsil	21480	-	-	-	-	-	-
			(salivary						
			gland)						
21	24200	-	-	-	-	-	-	-	-
	(parabronchial								
	lymph node)								
22	917600	nasopharynx,	-	-	-	-	-	23120	table
	(nasopharynx)	bronchi						(table)	

(table) (tabl